Vasogen to Conduct Year-end Conference Call
Toronto, Ontario - February 07, 2006
Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a leader in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, will release its year-end results after the close of the North American financial markets on Tuesday, February 14, 2006. A conference call will follow at 4:30 p.m. Eastern Time, during which management will provide a company update and discuss year-end results. Participants are invited to attend by connecting 10 minutes prior to the call to one of the following:
| Audio Web Cast* |
www.vasogen.com |
| Direct Dial |
416-695-5261 |
| Toll-free |
1-877-461-2816 |
A re-broadcast of the conference call may be accessed by:
| Audio Web Cast* |
www.vasogen.com |
| Direct Dial |
1-877-605-9320 Pin code: 9070 |
|
Windows Media Player required*
|
About Vasogen
Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. The Company is currently in the final stages of completing two pivotal phase III programs targeting large cardiovascular markets. The 2,400-patient phase III ACCLAIM trial is a 176-center international study designed to further investigate the use of Celacade™ technology to reduce the risk of death and hospitalization in patients with advanced chronic heart failure. The 550-patient phase III SIMPADICO trial, which was closed out early, is a 50-center North American study designed to further investigate the use of Celacade technology to improve intermittent claudication, a debilitating symptom associated with peripheral arterial disease. These phase III programs are designed to support regulatory approval in North America and commercialization in North America and Europe. Vasogen is also developing a new class of drugs for the treatment of neuro-inflammatory disorders. VP025, which has completed phase I clinical development, is the lead product candidate from this new class of drugs.
